Jun 12, 2026 08:10AM
May 14, 2026 10:55AM
May 14, 2026 10:55AM
May 14, 2026 09:15AM
Mar 2, 2026 07:00AM
Feb 3, 2026 08:32AM
Feb 3, 2026 08:30AM GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3
Jan 16, 2026 11:18AM
Jan 15, 2026 08:32AM
Jan 15, 2026 08:30AM
Dec 24, 2025 06:00AM
Dec 24, 2025 06:00AM
Dec 15, 2025 10:54AM
Nov 19, 2025 08:00AM GT Biopharma advances phase 1 trial for blood cancer treatment
Nov 19, 2025 08:00AM
Nov 14, 2025 09:00AM
Aug 14, 2025 04:05PM
Nov 14, 2024 04:00PM
Aug 14, 2024 04:05PM
Jun 27, 2024 09:17AM
Jun 27, 2024 09:15AM GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia
May 15, 2024 05:00PM
Mar 26, 2024 05:00PM
Dec 4, 2023 09:30AM
Nov 1, 2023 09:00AM
Aug 7, 2023 09:00AM
May 15, 2023 05:00PM
Mar 30, 2023 05:00PM GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
Feb 2, 2023 09:47AM
Feb 2, 2023 09:46AM
Aug 30, 2022 06:05PM
Aug 30, 2022 06:00PM
Jan 20, 2022 07:30AM
Jan 6, 2022 04:30PM
Dec 8, 2021 07:32AM GT Biopharma (GTBP) Shows Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021
Dec 8, 2021 07:30AM
Nov 30, 2021 07:30AM
Nov 24, 2021 04:05PM
Nov 10, 2021 04:10PM
Nov 8, 2021 07:30AM
Sep 20, 2021 07:00AM
Sep 15, 2021 07:08AM GT Biopharma (GTBP) Announces Updated Positive Safety Data From Phase 1 GTB-3550 Monotherapy TriKE™ Trial an Investigational Immunotherapy for Refractory Cancers to be Presented at ESMO
Sep 15, 2021 07:00AM
Sep 13, 2021 07:00AM
Sep 9, 2021 07:00AM
Sep 8, 2021 12:28PM
Aug 23, 2021 07:00AM
Aug 13, 2021 07:30AM
Aug 6, 2021 08:00AM GT Biopharma to Host Conference Call to Discuss Second Quarter 2021 Results
Aug 3, 2021 07:00AM

323,573 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All